The role of tadalafil in the management of sexual dysfunctions


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Erectile dysfunction (ED) has a significant negative impact on the quality of life of the patients and their partners. The sequence and regimens of ED therapy have become quite evident since the advent of phosphodiesterase type 5 inhibitors (PDE-5). However, there have been continued basic research of the efficacy and safety of these agents and studies aimed at new therapeutic goals. In recent years, the attention of researchers has shifted into a wider range of issues related to the personalized PDE-5 therapy, including sexual satisfaction, psychosocial variables (e.g., confidence, selfesteem, quality of relationships) and other potentially related factors. In particular, there are more and more new data on male sexual dysfunction. This review focuses on the relationship between erectile dysfunction and concomitant conditions: depressive symptoms, libido and sexual satisfaction disorders, ejaculation and orgasm abnormalities. The authors outline the possibilities and potential benefits of PDE-5 for patients with comorbid sexual dysfunction and depression with a special focus on tadalafil.

Full Text

Restricted Access

About the authors

E. A Efremov

N.A. Lopatkin Scientific Research Institute of Urology and Interventional Radiology - branch of NMRRC of Minzdrav of Russia

Dr.Med.Sci. Head of the Department of Andrology and Human Reproduction

E. V Kasatonova

N.A. Lopatkin Scientific Research Institute of Urology and Interventional Radiology - branch of NMRRC of Minzdrav of Russia

Email: kasatonova@yandex.ru
Researcher at the Department of Andrology and Human Reproduction

Ya. I Melnik

N.A. Lopatkin Scientific Research Institute of Urology and Interventional Radiology - branch of NMRRC of Minzdrav of Russia

Researcher at the Department of Andrology and Human Reproduction

A. A Nikushina

N.A. Lopatkin Scientific Research Institute of Urology and Interventional Radiology - branch of NMRRC of Minzdrav of Russia

Researcher at the Research and Methodology Department of Andrology and Human Reproduction

References

  1. Corona G., Mondaini N., Ungar A., Razzoli E., Rossi A., Fusco F. Phosphodiesterase type 5 (PDE5) inhibitors in erectile dysfunction: The proper drug for the proper patient. J Sex Med. 2011;8:3418-3432.
  2. Shim Y.S., Pae C.U., Cho K.J., Kim S.W., Kim J.C., Koh J.S. Effects of daily low-dose treatment with phosphodiesterase type 5 inhibitor on cognition, depression, somatization and erectile function in patients with erectile dysfunction: a double-blind, placebo-controlled study. Int J Impot Res. 2014;26(2):76-80. doi: 10.1038/ijir.2013.38.
  3. Porst H., Gacci M., Büttner H., Henneges C, Boess F. Tadalafil once daily in men with erectile dysfunction: an integrated analysis of data obtained from 1913 patients from six randomized, double-blind, placebo-controlled, clinical studies. Eur Urol. 2014;65(2):455-464. Doi: 10.1016/j. eururo.2013.09.037.
  4. McMahon C.G. Screening for erectile dysfunction in men with lifelong premature ejaculation--Is the Sexual Health Inventory for Men (SHIM) reliable? J. Sex Med. 2009;6(2):567-573. doi: 10.1111/j.1743-6109.2008.01092.x.
  5. Choi H., Kim J.H., Shim J.S., Park J.Y., Kang S.H., Moon D.G., Cheon J., Lee J.G., Kim J.J., Bae J.H. Comparison of the efficacy and safety of 5-mg once-daily versus 5-mg alternate-day tadalafil in men with erectile dysfunction and lower urinary tract symptoms. Int J. Impot Res. 2015;27(1):33-37. doi: 10.1038/ijir.2014.19.
  6. Wrishko R., Sorsaburu S., Wong D., Strawbridge A., McGill J. Safety, efficacy, and pharmacokinetic overview of low-dose daily administration of tadalafil. J. Sex Med. 2009;6(7):2039-2048. doi: 10.1111/j.1743-6109.2009.01301.x.
  7. Wang R., Burnett A.L., Heller W.H., Omori K., Kotera J., Kikkawa K., Yee S., Day W.W., DiDonato K., Peterson C.A. Selectivity of avanafil, a PDE5 inhibitor for the treatment of erectile dysfunction: implications for clinical safety and improved tolerability. J. Sex Med. 2012;9(8):2122-2129. doi: 10.1111/j.1743-6109.2012.02822.x.
  8. Bansal U.K., Jones C., Fuller T.W., Wessel C., Jackman S.V. The Efficacy of Tadalafil Daily vs on Demand in the Treatment of Erectile Dysfunction: A Systematic Review and Meta-analysis. Urology. 2017. pii: S0090-4295(17)30905-6. doi: 10.1016/j.urology.2017.08.031.
  9. Peng Z., Yang L., Dong Q., Wei Q., Liu L., Yang B. Efficacy and Safety of Tadalafil Once-a-Day versus Tadalafil On-Demand in Patients with Erectile Dysfunction: A Systematic Review and Meta-Analyses. Urol Int. 2017;99(3):343-352. doi: 10.1159/000477496.
  10. McMahon C. Comparison of efficacy, safety, and tolerability of on-demand tadalafil and daily dosed tadalafil for the treatment of erectile dysfunction. J. Sex Med. 2005;2(3):415-425; discussion 425-427. doi: 10.1111/j.1743-6109.2005.20360.x
  11. Rubio-Aurioles E., Porst H., Kim E.D., Montorsi F., Hackett G., Morales A.M., Stuckey B., Buttner H., West T.M., Huynh N.N., Lenero E., Burns P., Kopernicky V. A randomized open-label trial with a crossover comparison of sexual self-confidence and other treatment outcomes following tadalafil once a day vs. tadalafil or sildenafil on-demand in men with erectile dysfunction. J. Sex Med. 2012;9(5):1418-1429. doi: 10.1111/j.1743-6109.2012.02667.x.
  12. Shiri R., Koskimàki J., Tammela T.L., Hakkinen J., Auvinen A., Hakama M. Bidirectional relationship between depression and erectile dysfunction. J. Urol. 2007;177(2):669-673. doi: 10.1016/j.juro.2006.09.030.
  13. Seidman S.N., Roose S.P., Menza M.A., Shabsigh R., Rosen R.C. Treatment of erectile dysfunction in men with depressive symptoms: results of a placebo-controlled trial with sildenafil citrate. Am J. Psychiatry. 2001;158(10):1623- 1630. doi: 10.1176/appi.ajp.158.10.1623.
  14. Scranton R.E., Goldstein I., Stecher V.J. Erectile dysfunction diagnosis and treatment as a means to improve medication adherence and optimize comorbidity management. J. Sex Med. 2013;10(2):551-561. doi: 10.1111/j.1743-6109.2012.02998.x.
  15. Nicolosi A., Moreira E.D. Jr., Villa M., Glasser D.B. A population study of the association between sexual function, sexual satisfaction and depressive symptoms in men. J. Affect Disord. 2004;82:235-243. Doi: 10.1016/j. jad.2003.12.008.
  16. Yafi F.A., Jenkins L., Albersen M., Corona G., Isidori A.M., Goldfarb S., Maggi M., Nelson C.J., Parish S., Salonia A., Tan R., Mulhall J.P., Hellstrom W.J. Erectile dysfunction. Nature reviews Disease primers. 2016;2:16003. doi: 10.1038/nrdp.2016.3.
  17. Yao F., Huang Y., Zhang Y., Dong Y., Ma H., Deng C., Lin H., Liu D., Lu K. Subclinical endothelial dysfunction and low-grade inflammation play roles in the development of erectile dysfunction in young men with low risk of coronary heart disease. Int J. Androl. 2012;35(5):653-659. doi: 10.1111/j.1365-2605.2012.01273.x.
  18. Pizzi C., Manzoli L., Mancini S., Costa G.M. Analysis of potential predictors of depression among coronary heart disease risk factors including heart rate variability, markers of inflammation, and endothelial function. Eur Heart J. 2008;29(9):1110-1117. doi: 10.1093/eurheartj/ehn137.
  19. Khera M. Patients with testosterone deficit syndrome and depression. Arch Esp Urol. 2013;66(7):729-736.
  20. Corona G., Wu F. C., Rastrelli G., Lee D.M., Forti G., O’Connor D.B., O’ Neill T.W., Pendleton N., Bartfai G., Boonen S., Casanueva F.F., Finn J.D., Huhtaniemi I.T., Kula K., Punab M., Vanderschueren D., Rutter M.K., Maggi M. Low prolactin is associated with sexual dysfunction and psychological or metabolic disturbances in middle-aged and elderly men: the European Male Aging Study (EMAS). J. Sex Med. 2014;11(1):240-253. Doi: 10.1111/ jsm.12327.
  21. Chou P.S., Chou W.P., Chen M.C., Lai C.L., Wen Y.C., Yeh K.C., Chang W.P., Chou Y.H. Newly diagnosed erectile dysfunction and risk of depression: a population-based 5-year follow-up study in Taiwan. J. Sex Med. 2015;12(3):804-812. doi: 10.1111/jsm.12792.
  22. Seftel A.D., Sun P., Swindle R. The prevalence ofhypertension, hyperlipidemia, diabetes mellitus and depression in men with erectile dysfunction. J. Urol. 2004;171(1):2341-2345.
  23. Gandaglia G., Briganti A., Jackson G., Kloner RA., Montorsi F., Montorsi P., Vlachopoulos C. A systematic review of the association between erectile dysfunction and cardiovascular disease. Eur Urol. 2014;65(5):968-978. doi: 10.1016/j.eururo.2013.08.023.
  24. Клочай В.В., Крупин В.Н. Роль психоэмоциональных нарушений в патогенезе эректильной дисфункции при цереброваскулярной патологии. Медицинский альманах. 2010;2:61-65
  25. Комлев Д.С., Ямлихина Э.Г., Сайфуллина Л.И., Саттаров Ш.З., Нигматуллина А.Э., Кинзикеева А.А., Галяутдинова В.Р., Кабанова О.А., Мусин А.Г., Сахаутдинова Г.М. Возможности медикаментозной коррекции психологического статуса больных артериальной гипертонией с эректильной дисфункцией. Медицинский вестник Башкортостана. 2011;6(6):53-57
  26. Taylor M.J., Rudkin L., Bullemor-Day P., Lubin J., Chukwujekwu C., Hawton K. Strategies for managing sexual dysfunction induced by antidepressant medication. Cochrane Database Syst Rev. 2013;(5):CD003382. doi: 10.1002/14651858.CD003382.pub3.
  27. Paduch D.A., Bolyakov A., Beardsworth A., Watts S.D. Factors associated with ejaculatory and orgasmic dysfunction in men with erectile dysfunction: analysis of clinical trials involving the phosphodiesterase type 5 inhibitor tadalafil. BJU Int. 2012;109(7):1060-1067. doi: 10.1111/j.1464- 410X.2011.10504.x.
  28. Paduch D.A., Bolyakov A., Polzer P.K., Watts S.D. Effects of 12 weeks of tadalafil treatment on ejaculatory and orgasmic dysfunction and sexual satisfaction in patients with mild to severe erectile dysfunction: integrated analysis of 17 placebo-controlled studies. BJU Int. 2013;111(2):334-343. doi: 10.1111/j.1464-410X.2012.11656.x.
  29. Sontag A., Ni X., Althof S.E., Rosen R.C. Relationship between erectile function and sexual self-confidence: a path analytic model in men being treated with tadalafil. Int J Impot Res. 2014;26(1):7-12. Doi: 10.1038/ ijir.2013.31.
  30. Giuliano F., Oelke M., Jungwirth A., Hatzimouratidis K., Watts S., Cox D., Viktrup L. Tadalafil once daily improves ejaculatory function, erectile function, and sexual satisfaction in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia and erectile dysfunction: results from a randomized, placebo- and tamsulosin-controlled, 12-week doubleblind study. J Sex Med. 2013;10(3):857-865. doi: 10.1111/jsm.12039.
  31. Porst H., Montorsi F., Rosen R.C., Gaynor L., Grupe S., Alexander J. The premature ejaculation prevalence and attitudes (PEPA) survey: prevalence, comorbidities, and professional help-seeking. Eur Urol. 2007;51:816-823. discussion 824.
  32. Althof S.E., McMahon C.G., Waldinger M.D., Serefoglu E.C., Shindel A.W., Adaikan P.G., Becher E., Dean J., Giuliano F., Hellstrom W.J., Giraldi A., Glina S., Incrocci L., Jannini E., McCabe M., Parish S., Rowland D., Segraves R.T., Sharlip I., Torres L.O. An update of the International Society of Sexual Medicine’s guidelines for the diagnosis and treatment of premature ejaculation (PE). J Sex Med. 2014;11(6):1392-1422. doi: 10.1111/jsm.12504.
  33. Corona G., Petrone L., Mannucci E., Jannini E.A., Mansani R., Magini A., Giommi R., Forti G., Maggi M. Psycho-biological correlates of rapid ejaculation in patients attending an andrologic unit for sexual dysfunctions. Eur Urol. 2004;46:615-622. doi: 10.1016/j.eururo.2004.07.001
  34. el-Sakka A.I. Severity of erectile dysfunction at presentation: effect of premature ejaculation and low desire. Urology. 2008;71(1):94-98. doi: 10.1016/j.urology.2007.09.006.
  35. Buvat J. Pathophysiology ofpremature ejaculation. J Sex Med. 2011;8(4):316- 327. doi: 10.1111/j.1743-6109.2011.02384.x.
  36. Porst H., McMahon C.G., Althof S.E., Sharlip I., Bull S., Aquilina J.W., Tesfaye F., Rivas D.A. Baseline characteristics and treatment outcomes for men with acquired or lifelong premature ejaculation with mild or no erectile dysfunction: integrated analyses of two phase 3 dapoxetine trials. J Sex Med. 2010;7(6):2231-2242. doi: 10.1111/j.1743-6109.2010.01820.x.
  37. Ozcan L., Polat E.C., Onen E., Kocaaslan R., Otunctemur A., Cekmen M., Eraldemir C., Ozbek E. Effects of tadalafil 5 mg dosed once daily in men with premature ejaculation. Urologia Internationalis. 2017;98(2):210-214. doi: 10.1159/000445839.
  38. Ахвледиани Н.Д. Лечение вторичного преждевременного семяизвержения, связанного с эректильной дисфункцией. Медицинский совет. 2016;5:94-97
  39. Гамидов С.И., Щербаков Д.В., Тажетдинов О.Х., Приймак Д.В., Павловичев А.А. Эффективность применения тадалафила у больных с преждевременной эякуляцией в сочетании с эректильной дисфункцией. Вестник Российского государственного медицинского университета. 2010;6:54-58
  40. Alwaal A., Breyer B.N., Lue T.F. Normal male sexual function: emphasis on orgasm and ejaculation. Fertility and sterility. 2015;104(5):1051-1060. doi: 10.1016/j.fertnstert.2015.08.033
  41. Shabsigh R., Seftel A.D., Rosen R.C., Porst H., Ahuja S., Deeley M.C., Garcia C.S., Giuliano F. Review of time of onset and duration of clinical efficacy of phosphodiesterase type 5 inhibitors in treatment of erectile dysfunction. Urology. 2006;68(4):689-96. doi: 10.1016/j.urology.2006.05.009.
  42. Setter S.M., Iltz J.L., Fincham J.E., Campbell R.K., Baker D.E. Phosphodiesterase 5 inhibitors for erectile dysfunction. Ann Pharmacother. 2005;39(7-8):1286-1295. doi: 10.1345/aph.1E487.
  43. Kirby R.S., Lowe D., Bultitude M.I., Shuttleworth K.E. Intra-prostatic urinary reflux: an aetiological factor in abacterial prostatitis. British Journal of Urology. 1982;54(6):729-731. doi: 10.1111/j.1464-410X. 1982.tb13635.x.
  44. La Vignera S., Vicari E., Condorelli R., DAgata R., CalogeroA.E. Hypertrophic-congestive and fibro-sclerotic ultrasound variants of male accessory gland infection have different sperm output. Journal of Endocrinological Investigation. 2011;34(10):e330-e335. doi: 10.1007/BF03346729.
  45. Ückert S., Waldkirch E.S., Sonnenberg J.E., Sandner P., Kuczyk M.A., Hedlund P. Expression and distribution of phosphodiesterase isoenzymes in the human seminal vesicles. J Sex Med. 2011;8(11):3058-3065. Doi:10.1111/ j.1743-6109.2011.02397.x.
  46. La Vignera S., Condorelli R.A., Mongioi L.M., Calogero A.E. Chronic Administration of Tadalafil Improves the Symptoms of Patients with Amicrobic MAGI: An Open Study. International Journal of Endocrinology. 2017;2017:3848545. doi: 10.1155/2017/3848545.
  47. Grimsley S.J., Khan M.H., Jones G.E. Mechanism of Phosphodiesterase 5 inhibitor relief of prostatitis symptoms. Med Hypotheses. 2007;69(1):25-26. doi: 10.1016/j.mehy.2006.11.040.
  48. Ефремов Е.А., Дорофеев С.Д., Панюшкин С.М., Бедретдинова Д.А. Сексуальные и психосоматические нарушения при хроническом простатите. Медицинский совет. 2008;9-10:30-36
  49. Corvasce A., Albino G., Leonetti T., Buonomo A.F., Marucco E.C. Once-a-day Tadalafiladministration improves the spermogram parameters in fertile patients. Arch Ital Urol Androl. 2015;87(3):210-213. Doi: 10.4081/ aiua.2015.3.210.
  50. Hellstrom W.J., Overstreet J.W., Yu A., Saikali K., Shen W., Beasley C.M. Jr., Watkins V.S. Tadalafil has no detrimental effect on human spermatogenesis or reproductive hormones. The Journal of Urology. 2003;170(3):887-891. doi: 10.1097/01.ju.0000081053.97792.da.
  51. Wayman C., Phillips S., Lunny C., Webb T., Fawcett L., Baxendale R., Burgess G. Phosphodiesterase 11 (PDE11) regulation of spermatozoa physiology. Int J. Impot Res. 2005;17(3):216-223. doi: 10.1038/sj.ijir.3901307.
  52. Завод «Тева Фармацевтические предприятия Лтд.» (Кфар Саба, Израиль), на котором производится препарат ДИНАМИКО ЛОНГ, сертифицирован по стандарту GMP, который устанавливает требования к организации производства и контроля качества лекарственных средств для медицинского применения. Сертификат GMP-00491/18/IL от 31.01.2018.
  53. Верткин А.Л., Пушкарь Д.Ю., Тополянский А.В., Сегал А.С. Эректильная дисфункция. Лечащий врач. 2003;7:54-60
  54. Инструкция по применению лекарственного препарата для медицинского применения ДИНАМИКО ЛОНГ
  55. Porst H., Padma-Nathan H., Giuliano F., Anglin G., Varanese L., Rosen R. Efficacy of tadalafil for the treatment of erectile dysfunction at 24 and 36 hours after dosing: a randomized controlled trial. Urology. 2003;62: 121-125.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies